Illumina (ILMN) Projected to Post Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $1.0997 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Illumina Stock Performance

Shares of ILMN opened at $149.86 on Thursday. Illumina has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The company has a market cap of $22.90 billion, a PE ratio of 33.60, a price-to-earnings-growth ratio of 2.52 and a beta of 1.41. The stock has a 50-day moving average price of $137.06 and a 200-day moving average price of $114.34.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ILMN shares. Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday, October 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Canaccord Genuity Group raised their price target on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday. Finally, Barclays upped their price objective on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus price target of $127.18.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new stake in Illumina during the 3rd quarter valued at $539,000. Captrust Financial Advisors raised its stake in shares of Illumina by 21.0% during the third quarter. Captrust Financial Advisors now owns 29,464 shares of the life sciences company’s stock valued at $2,798,000 after acquiring an additional 5,115 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Illumina by 22.1% during the third quarter. Coldstream Capital Management Inc. now owns 4,668 shares of the life sciences company’s stock valued at $443,000 after acquiring an additional 845 shares during the last quarter. Danske Bank A S purchased a new stake in shares of Illumina during the third quarter worth about $6,408,000. Finally, Advisory Services Network LLC bought a new stake in shares of Illumina in the third quarter worth about $102,000. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.